$ Value
$0
Shares
25,000
Price
$0
Filed
Jun 2
Insider
Name
Fairmount Funds Management LLC
Title
—
CIK
0001802528
Roles
Transaction Details
Transaction Date
2025-05-29
Code
A
Table
Derivative
Ownership
Indirect
Equity Swap
No
Shares After
25,000
Footnotes
This option represents a right to purchase 25,000 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 29, 2025 until such time as the option is 100% vested, subject to Peter Harwin's continuous service with the Issuer at each vesting date. | Under Mr. Harwin's arrangement with Fairmount Funds Management LLC (the "Adviser"), Mr. Harwin holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying common stock, except to the extent of his pecuniary interest therein. | This option represents a right to purchase 25,000 shares of the Issuer's common stock, which will vest and become exercisable in 12 equal monthly installments following May 29, 2025 until such time as the option is 100% vested, subject to Tomas Kiselak's continuous service with the Issuer at each vesting date. | Under Mr. Kiselak's arrangement with Fairmount Funds Management LLC (the "Adviser"), Mr. Kiselak holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). Mr. Kiselak is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Kiselak therefore disclaims beneficial ownership of the option and underlying common stock, except to the extent of his pecuniary interest therein.
Filing Info
Fairmount Funds Management LLC's History
| Date | Ticker | Type | Value |
|---|---|---|---|
| 2026-03-31 | COGT | C | — |
| 2026-03-31 | COGT | ▼ | $242.6M |
| 2026-03-31 | COGT | C | $0 |
| 2026-03-31 | ZBIO | ▲ | $3.0M |
| 2026-03-23 | DMRA | A | $0 |
| 2025-10-23 | VRDN | ▲ | $10.0M |
| 2025-10-07 | ZBIO | ▲ | $6.0M |
| 2025-10-06 | JBIO | A | $12.2M |
| 2025-10-06 | JBIO | A | $7.8M |
| 2025-09-17 | ORKA | A | $5.0M |
Other Insiders at SYRE (90d)
| Insider | Bought | Sold | Last |
|---|---|---|---|
|
Turtle Cameron
Chief Executive Officer
|
— | $740K | 2026-04-01 |
|
Burrows Scott L
Chief Financial Officer
|
— | $370K | 2026-04-01 |
|
Sloan Sheldon
Chief Medical Officer
|
— | $398K | 2026-04-01 |